The department was founded in 1992. Under the leadership of former directors Prof. Chen Changchun, Prof. Pan Wensheng, and Prof. Tan Yunshan, it has been under constant development for over 20 years and now it has 24 doctors and 25 technicians, covering a working area of about 1500 square meters. The current director is chief physician Hou Yingyong, and chief physician Ji Yuan and Prof. Chen Gang are deputy directors. There are 7 doctors with senior professional titles, 5 attending physicians, 2 doctoral supervisors, 3 master supervisors, 46.7% with doctoral degree and 30.7% with master’s degree. At present, 27 physicians are receiving professional trainings in its base. Among the technicians, there are 4 senior technicians, 21 technicians, 1 with doctoral degree and 2 with master’s degree. The number of annual pathological diagnoses has exceeded 100,000 in 2015, ranking top in the country. Every year, they complete about 8600 cases of intraoperative frozen section, 9000 emergency cases, 5000 group consultations, and 300 immuno-histochemistry examinations. In 2015, the total number reaches 17000. The sources of specimens are extensive, including surgical excision, endoscopic biopsy and fine needle aspiration etc. Cellular pathology items include puncture (20,000 cases per year), exfoliative cytology (5500), liquid-based cytology (12,000) and gynecological examination (10,000).
The department consists of four sections; histopathology, immunopathology, molecular pathology and cytopathology. Meanwhile, it participates in the tissue bank construction of Zhongshan Hospital, and has built pathology network platforms with some branch hospitals, and is jointly building the National Tele-Pathology Consultation System and remote communication platforms with several foreign hospitals. In molecular pathology testing, it has carried out in situ hybridization and fluorescence in situ hybridization, and has built a clinical PCR laboratory in accordance with the Basic Setting Standards for Clinical Genetic Expansion Testing Laboratory. It strictly abides by the lab norms to ensure quality and make clinical diagnosis and treatment more scientific. Equipped with various necessary instruments and devices, a number of molecular pathology testing items applied in pathological diagnosis and targeted therapy are carried out, such as KIT, PDGFRA, K-ras, N-ras, B-raf, PIK3CA, EGFR gene mutation testing, and IgH, TCR gene rearrangement testing, as well as CISH and FISH testing of EBER, HER2, SS18, bcl-2, bcl6, c-myc, MALT, EWS, MDM2, CDK4, DDIT3, CCND1, MET, EGFR, Urovysion, PIK3CA, FOXO1, FUS, P53, D13S319, D13S25, RB1, 1q21, ATM, CSP12, ALK, ROS1. It has applied for joining external quality control projects at home and abroad and has got all admissions. Now it is undertaking preliminary experiments and preparation work of second-generation sequencing.
Teaching and Academic Research Achievements
The department is responsible for teaching students of different backgrounds, including refresher pathologists, exchange physicians from other bases, interns from other departments and Master students of this department. Every year, it takes in 3 to 6 refreshers, 1to 3 master students, 5 to 8 base doctors, and nearly 100 exchange doctors. They conduct national continuing education programs in succession over the years, systematically introducing fine needle aspiration and intraoperative frozen section [2014-01-04-075 (state)], and the role of pathology in the diagnosis and treatment of multidisciplinary teams [2015-01-04-021 (state)]. Since it became Shanghai Pathology Specialty Base in 2010, it has cultivated a great number of pathologists. In 2014, it became Shanghai Specialty Base of General Pathology, Pulmonary Disease Pathology, Digestive System Pathology and Lymphatic System Pathology. Breast Pathology Sub-specialty was set up in the same year.
It has undertaken 11 projects funded by the National Natural Science Foundation, and several by the Science and Technology Commission of Shanghai Municipality and Shanghai Bureau of Health. They have published several articles in famous foreign journals like Nat Med, Am J Respir Crit Care Med, Modern Pathology, Histopathology, and domestic ones like Chinese Journal of Pathology and Chinese Journal of Transplantation. Over the years, they have delivered many important speeches in the Pathology Annual Meeting of Chinese Medical Association. They have invented several technologies and methods and won over 10 patents. Moreover, they have participated in the formulation of various disease guidelines, such as WHO Pathological Classification of Lung Cancer and Thymic Tumor, National Pathological Diagnosis Criteria of Pneumoconioses, China’s Consensus on the Diagnosis and Treatment of Gastrointestinal Stromal Tumor, China's Expert Consensus on the Gene Mutation Testing Epidermal Growth Factor Receptor of Patients with Non-small Cell Lung Cancer, and Expert Consensus on Pathological Diagnosis of Primary Liver Cancer. They have compiled Gastrointestinal Stromal Tumors and Hepatobiliary and Pancreatic Tumors: Pathology, Imaging and Clinical as chief editor, and Mediastinal Lymphoma, Pathology of Pleural Mesothelioma and Lung Tumor as co-editor. Meanwhile, they have participated in the translation of several monographs such as Management of Soft Tissue Sarcoma. With many achievements in science and technology appraised, we have won several awards including the third Prize of Shanghai Scientific and Technological Progress Award.